HTB-DRIVE is a practical and hands-on approach to high throughput drug screening. We provide you with a 384-well plate divided into two halves. Each half contains 32 drugs at five different concentrations, allowing the testing of multiple variables.
Participating researchers are required to bring a cell suspension that is ready-to-plate at a specific cell density. We then use our cutting-edge robotics to place the cells onto the plate. After incubation with the drugs for a period of 3 days, cell viability is measured using CellTiter-Glo (CTG).
Fill out this application form to participate.
While the 32 drugs provided may seem limited, they represent a curated selection from our extensive oncology drug library. This includes 15 kinase inhibitors, DNA-damaging drugs, epigenetic modifiers, and apoptosis-inducers, among others. See the complete list below for your perusal.
The type of samples you want to test is entirely up to you. You may choose to test a wild-type versus mutant, healthy versus diseased, or even explore drug combinations using DMSO and a drug of your interest. The possibilities are endless.
Participating researchers are required to bring a cell suspension that is ready-to-plate at a specific cell density. We then use our cutting-edge robotics to place the cells onto the plate. After incubation with the drugs for a period of 3 days, cell viability is measured using CellTiter-Glo (CTG).
Interested researchers are encouraged to review our drug list to see if any drugs align with their current projects. Even if your project isn't directly related, the experience gained from high-throughput screening will be invaluable to your research.
To apply, please fill out a short project description form and submit your request by July 1. We will review all applications and select up to 5 projects by August 15. Preference will be given to new customers, particularly new PIs and labs that haven't previously engaged in a project with us. The potential for your project to evolve into a larger screening project in the future will also be a key consideration during the evaluation process.
The actual screening is scheduled to begin in September this year. Join us in driving forward the future of high throughput drug screening with HTB-DRIVE!